SPOP Promotes SRRM1 Ubiquitination and Degradation to Suppress Prostate Cancer Progression by regula

来源 :2019中国肿瘤学大会 | 被引量 : 0次 | 上传用户:haha123456hehe
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective Prostate cancer accounts for 19%of estimated new cancer cases in men and is the third primary cause of male cancer-related mortality after lung cancer and colon cancer in United States.
其他文献
Objective Hepatoblastoma(HB)is the most common liver tumors in children,accounting for more than 65%of childhood liver malignancies and about 1%of all childhood tumors.It usually originates from immat
Objective Objective: Monocarboxylate transporter 4(MCT4),also known as SLC16A3,is a member of the MCT family.MCT4 is one the key transporters involved in the regulation of lactate and proton release f
目的 肝癌是世界上最常见的恶性肿瘤之一,其发病率位居恶性肿瘤第六位,死亡率位居恶性肿瘤第四位。进一步深入探索肝癌的发生、发展机制,对优化肝癌预防和治疗策略、减少肝癌死亡率具有重要意义。
Objective Objects: to investigate the role of CDK6 and microRNA-320d in diffuse large B cell lymphoma(DLBCL)and the relationship between CDK6 and miRNA-320d.
Objective Gastric cancer(GC)is the second most commonly diagnosed cancer among men and the third among women,and it is the second leading cause of cancer-related deaths worldwide.
目的 顺铂是胃癌化学治疗的一线药物.先天性和获得性的抵抗极大地影响了患者的预后.microRNA(miRNA)可通过同时调控多条信号通路及肿瘤恶性生物学行为,从而影响顺铂的细胞毒性.因此,探索基于miRNA 的新治疗策略对于GC 来说是非常紧迫的.
会议
Objective Accumulating studies have reported the aberrant expression of SLC5A1 is a negative prognostic factor to various cancer patients.
Objective Background: Breast cancer is the most commonly diagnosed female cancer and the 6th leading cause of cancer-related death in Chinese women.
Objective Colorectal cancer is one of the most common cancer worldwide.The detailed molecular mechanisms related to colorectal cancer tumorigenesis and progression remain poorly understood.
Objective Emerging evidence has indicated that deregulation of long non-coding RNAs(lncRNAs)can contribute to the progression of human cancers,including hepatocellular carcinoma(HCC).